Literature DB >> 18269231

Synthesis and in vitro evaluation of a rhenium-cyclized somatostatin derivative series.

Heather M Bigott-Hennkens1, Sulochana Junnotula, Lixin Ma, Fabio Gallazzi, Michael R Lewis, Silvia S Jurisson.   

Abstract

The structure-activity relationships of a series of rhenium (Re)-cyclized octreotide derivatives are described. The effects of changes in the peptide sequence, N-terminus, and C-terminus on metal cyclization, as well as binding to the somatostatin receptor, were investigated. Each peptide complex was found to have an integrated Re(V) core with a single metal oxo group, two coordination sites filled by the cysteine sulfhydryls, and another by the amide nitrogen of Phe (3)/Tyr (3). The final coordination site was determined by the peptide N-terminus: the N-terminal amine coordinated for N-NH 2 peptides and the amide nitrogen of Thr (6) for peptides with acetylated N-termini. Re-cyclization of the octreotide derivatives led to structural perturbations of the somatostatin receptor-binding sequence relative to the Re-free disulfide analogues, resulting in reduced binding affinities. The findings presented herein demonstrate the importance of understanding the consequences of structural modifications when designing metal-peptide complexes for somatostatin receptor targeting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269231     DOI: 10.1021/jm701056x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  In vitro structure-activity relationship of Re-cyclized octreotide analogues.

Authors:  Shorouk F Dannoon; Heather M Bigott-Hennkens; Lixin Ma; Fabio Gallazzi; Michael R Lewis; Silvia S Jurisson
Journal:  Nucl Med Biol       Date:  2010-07       Impact factor: 2.408

2.  Labeling, stability and biodistribution studies of 99mTc-cyclized Tyr3-octreotate derivatives.

Authors:  Heather M Bigott-Hennkens; Shorouk F Dannoon; Samantha M Noll; Varyanna C Ruthengael; Silvia S Jurisson; Michael R Lewis
Journal:  Nucl Med Biol       Date:  2010-12-03       Impact factor: 2.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.